B. C. Allen, T. R. Covington, and H. J. Clewell, Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform, Toxicology, vol.111, issue.1-3, pp.289-303, 1996.
DOI : 10.1016/0300-483X(96)03383-5

M. E. Andersen, I. Clewell, H. J. , F. , and C. B. , Applying Simulation Modeling to Problems in Toxicology and Risk Assessment: A Short Perspective, Toxicology and Applied Pharmacology, vol.133, issue.2, 1995.
DOI : 10.1006/taap.1995.1140

M. A. Babich, Risk assessment of low-level chemical exposures from consumer products under the U.S. Consumer Product Safety Commission chronic hazard guidelines, Environ Health Perspect, vol.106, pp.387-90, 1998.

H. A. Barton, C. D. Flemming, and J. C. Lipscomb, Evaluating human variability in chemical risk assessment: hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene, Toxicology, vol.111, issue.1-3, pp.271-87, 1996.
DOI : 10.1016/0300-483X(96)03382-3

M. Beliveau, J. Lipscomb, R. Tardif, and K. Krishnan, Quantitative Structure???Property Relationships for Interspecies Extrapolation of the Inhalation Pharmacokinetics of Organic Chemicals, Chemical Research in Toxicology, vol.18, issue.3, pp.475-485, 2005.
DOI : 10.1021/tx049722k

B. J. Blaauboer, M. D. Barratt, H. , and B. J. , The Integrated Use of Alternative Methods in Toxicological Risk Evaluation: ECVAM Integrated Testing Strategies Task Force Report 1, ATLA-Altern. Lab. Anim, vol.27, pp.229-237, 1999.

B. J. Blaauboer, M. K. Bayliss, J. V. Castell, C. T. Evelo, J. M. Frazier et al., The use of Biokinetics and In Vitro Methods in Toxicological Risk Evaluation, ATLA, vol.24, pp.473-497, 1996.

A. R. Boobis, S. M. Cohen, V. Dellarco, D. Mcgregor, M. E. Meek et al., IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans, Critical Reviews in Toxicology, vol.34, issue.10, pp.781-92, 2006.
DOI : 10.1080/10408440591007278

A. R. Boobis, J. E. Doe, B. Heinrich-hirsch, M. E. Meek, S. Munn et al., IPCS framework for analysing the relevance of a non-cancer mode of action for humans, Crit Rev Toxicol, 2007.

F. Campolongo and A. Saltelli, Sensitivity analysis of an environmental model; a worked application of different analysis methods. Reliability Engineering and System Safety, pp.49-69, 1997.

W. A. Chiu, H. A. Barton, R. S. Dewoskin, P. Schlosser, C. M. Thompson et al., Evaluation of physiologically based pharmacokinetic models for use in risk assessment, Journal of Applied Toxicology, vol.234, issue.3, pp.218-237, 2007.
DOI : 10.1002/jat.1225

W. A. Chiu, J. C. Caldwell, N. Keshava, and C. S. Scott, Key Scientific Issues in the Health Risk Assessment of Trichloroethylene, Environmental Health Perspectives, vol.114, issue.9, pp.1445-1454, 2006.
DOI : 10.1289/ehp.8690

K. Cho, S. Shin, W. Kolch, and O. Wolkenhauer, Experimental Design in Systems Biology, Based on Parameter Sensitivity Analysis Using a Monte Carlo Method: A Case Study for the TNF??-Mediated NF-?? B Signal Transduction Pathway, SIMULATION, vol.79, issue.12, pp.726-739, 2003.
DOI : 10.1177/0037549703040943

L. H. Clark, R. W. Setzer, and H. A. Barton, Framework for Evaluation of Physiologically-Based Pharmacokinetic Models for Use in Safety or Risk Assessment, Risk Analysis, vol.20, issue.6, pp.1697-717, 2004.
DOI : 10.1007/BF00332395

H. J. Clewell, M. E. Andersen, and H. A. Barton, A Consistent Approach for the Application of Pharmacokinetic Modeling in Cancer and Noncancer Risk Assessment, Environmental Health Perspectives, vol.110, issue.1, pp.85-93, 2002.
DOI : 10.1289/ehp.0211085

H. J. Clewell, M. E. Andersen, R. J. Wills, and L. Latriano, A physiologically based pharmacokinetic model for retinoic acid and its metabolites, Journal of the American Academy of Dermatology, vol.36, issue.3, pp.77-85, 1997.
DOI : 10.1016/S0190-9622(97)70063-X

H. J. Clewell, J. M. Gearhart, P. R. Gentry, T. R. Covington, C. B. Vanlandingham et al., Evaluation of the Uncertainty in an Oral Reference Dose for Methylmercury Due to Interindividual Variability in Pharmacokinetics, Risk Analysis, vol.44, issue.109, pp.547-58, 1999.
DOI : 10.1016/0300-483X(96)03383-5

H. J. Clewell, J. Teeguarden, T. Mcdonald, R. Sarangapani, G. Lawrence et al., Review and Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry, Critical Reviews in Toxicology, vol.5, issue.3, pp.329-89, 2002.
DOI : 10.1080/027868200303948

I. Clewell, H. J. Andersen, and M. E. , Dose, species and route extrapolation using physiologically-based pharmacokinetic modeling, Drinking Water and Health, vol.8, pp.159-184, 1987.

C. Cobelli, E. R. Carson, L. Finkelstein, and M. S. Leaning, Validation of simple and complex models in physiology and medicine, Am J Physiol, vol.246, pp.259-66, 1984.

L. A. Cox and . Jr, Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis, Environmental Health Perspectives, vol.104, issue.Suppl 6, pp.1413-1442, 1996.
DOI : 10.1289/ehp.961041413

G. A. Csanady and J. G. Filser, A Physiological Toxicokinetic Model for Inhaled Propylene Oxide in Rat and Human with Special Emphasis on the Nose, Toxicological Sciences, vol.95, issue.1, pp.37-62, 2007.
DOI : 10.1093/toxsci/kfl140

J. Dejongh, A. Forsby, J. B. Houston, M. Beckman, R. Combes et al., An Integrated Approach to the Prediction of Systemic Toxicity using Computer-based Biokinetic Models and Biological In vitro Test Methods: Overview of a Prevalidation Study Based on the ECITTS Project, Toxicology in Vitro, vol.13, issue.4-5, pp.549-554, 1999.
DOI : 10.1016/S0887-2333(99)00030-2

J. I. Delic, P. D. Lilly, A. J. Macdonald, and G. D. Loizou, The Utility of PBPK in the Safety Assessment of Chloroform and Carbon Tetrachloride, Regulatory Toxicology and Pharmacology, vol.32, issue.2, pp.144-55, 2000.
DOI : 10.1006/rtph.2000.1419

R. S. Dewoskin, PBPK models in risk assessment???A focus on chloroprene, Chemico-Biological Interactions, vol.166, issue.1-3, 2007.
DOI : 10.1016/j.cbi.2007.01.016

. Pharmacokinetic, Physiologically Based Pharmacokinetic Models in Integrated Risk Information System Assessments, Toxicokinetics and Risk Assessment, pp.301-348

S. J. Franks, A mathematical model for the absorption and metabolism of formaldehyde vapour by humans, Toxicology and Applied Pharmacology, vol.206, issue.3, pp.309-329, 2005.
DOI : 10.1016/j.taap.2004.11.012

S. J. Franks, M. K. Spendiff, J. Cocker, and G. D. Loizou, Physiologically based pharmacokinetic modelling of human exposure to 2-butoxyethanol, Toxicology Letters, vol.162, issue.2-3, pp.164-73, 2006.
DOI : 10.1016/j.toxlet.2005.09.012

P. G. Georgopoulos, A. Roy, and M. A. Gallo, Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models, J. Expos. Anal. Environ. Epidem, vol.4, pp.309-328, 1994.

I. Gueorguieva, L. Aarons, K. Ogungbenro, K. M. Jorga, T. Rodgers et al., Optimal Design for Multivariate Response Pharmacokinetic Models, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.2, pp.97-124, 2006.
DOI : 10.1007/s10928-006-9009-1

U. Gundert-remy and C. Sonich-mullin, The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective, Science of The Total Environment, vol.288, issue.1-2, pp.3-11, 2002.
DOI : 10.1016/S0048-9697(01)01108-1

M. S. Lee, T. H. Faller, P. E. Kreuzer, W. Kessler, G. A. Csanady et al., Propylene Oxide in Blood and Soluble Nonprotein Thiols in Nasal Mucosa and Other Tissues of Male Fischer 344/N Rats Exposed to Propylene Oxide Vapors--Relevance of Glutathione Depletion for Propylene Oxide-Induced Rat Nasal Tumors, Toxicological Sciences, vol.83, issue.1, pp.177-89, 2005.
DOI : 10.1093/toxsci/kfi006

B. Meek, A. Renwick, and C. Sonich-mullin, Practical application of kinetic data in risk assessment???an IPCS initiative, Toxicology Letters, vol.138, issue.1-2, pp.151-60, 2003.
DOI : 10.1016/S0378-4274(02)00371-5

M. E. Meek, J. R. Bucher, S. M. Cohen, V. Dellarco, R. N. Hill et al., A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action, Critical Reviews in Toxicology, vol.67, issue.2, pp.591-653, 2003.
DOI : 10.1080/15287399409531914

M. E. Meek and A. Renwick, Guidance for the development of chemical specific adjustment factors -integration with mode of action frameworks Informa Healthcare, 2006.

M. E. Meek, A. Renwick, E. Ohanian, M. Dourson, B. Lake et al., Guidelines for application of chemical specific adjustment factors (CSAF) in dose/concentration response assessment, Comments in Toxicology, vol.7, pp.575-590, 2001.

M. E. Meek, A. Renwick, E. Ohanian, M. Dourson, B. Lake et al., Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicol, pp.181-182, 2002.

I. A. Nestorov, L. J. Aarons, P. A. Arundel, R. , and M. , Lumping of whole-body physiologically based pharmacokinetic models, Journal of Pharmacokinetics and Pharmacodynamics, vol.26, issue.1, pp.21-46, 1998.
DOI : 10.1023/A:1023272707390

N. Oreskes, Evaluation (not validation) of quantitative models, Environmental Health Perspectives, vol.106, issue.Suppl 6, pp.1453-60, 1998.
DOI : 10.1289/ehp.98106s61453

S. Osterman-golkar, K. Czene, M. S. Lee, T. H. Faller, G. A. Csanady et al., Dosimetry by means of DNA and hemoglobin adducts in propylene oxide-exposed rats, Toxicology and Applied Pharmacology, vol.191, issue.3, pp.245-54, 2003.
DOI : 10.1016/S0041-008X(03)00253-9

C. J. Portier and C. M. Lyles, Practicing safe modeling: GLP for biologically based mechanistic models, Environmental Health Perspectives, vol.104, issue.8, 1996.
DOI : 10.1289/ehp.96104806

A. Rescigno and J. S. Beck, The use and abuse of models, Journal of Pharmacokinetics and Biopharmaceutics, vol.210, issue.3, pp.327-371, 1987.
DOI : 10.1007/BF01066325

M. Rowland, L. Balant, and C. Peck, Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science, Annual Review of Pharmacology and Toxicology, vol.51, issue.1, pp.1-12, 2002.
DOI : 10.1146/annurev-pharmtox-010510-100540

C. Sonich-mullin, R. Fielder, J. Wiltse, K. Baetcke, J. Dempsey et al., IPCS Conceptual Framework for Evaluating a Mode of Action for Chemical Carcinogenesis, Regulatory Toxicology and Pharmacology, vol.34, issue.2, pp.146-52, 2001.
DOI : 10.1006/rtph.2001.1493

U. Epa, Update to the Health Assessment Document and Addendum for Dichloromethane (Methylene Chloride): Pharmacokinetics, Mechanism of Action, and Epidemiology, External Review Draft. EPA, vol.600, pp.8-87, 1987.

U. Epa, Risk Assessment Guidance for Superfund Human Health Evaluation Manual (Part A) EPA, pp.1-89, 1989.

U. Epa, Guidelines for Carcinogen Risk Assessment (Final) EPA, 2005.

U. Epa, Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final Report), 2006.